Lab guide · Neuropeptides
What Is Adamax? Adamantane-Modified Semax Analogue Research Overview
What is Adamax? It is a designer analogue of Semax, Ac-Met-Glu-His-Phe-Pro-Gly-Pro with an adamantane-containing C-terminal group, with the formula C50H69N11O11S and a mass of about 1032 Da. This guide explains what is chemically defined, why two different molecules are sold under the same name, and why no peer-reviewed study of Adamax itself was found.
Key takeaways
- Adamax (1032 Da) is Ac-MEHFPGP linked to an adamantane-containing C-terminal unit, formula C50H69N11O11S, molar mass 1032.23 g/mol.
- A second material sold as “Adamax” at 984 Da is a different molecule, acetylated Semax extended with Ala-Gly and no adamantane, so mass must be confirmed.
- No peer-reviewed literature on Adamax itself and no CAS number were found; the rationale is extrapolated from Semax and the research peptide P021.
- It has been identified as a designer drug in border seizures and has been proposed for prescription classification in New Zealand.
What is Adamax?
So, what is Adamax? Adamax is a synthetic peptide derivative described as a designer analogue of Semax, modified with the N-terminal and C-terminal modifications found in Peptide 021 (Wikipedia entry for Adamax). Its structure is given as Ac-MEHFPGP linked to an adamantane-containing unit with a terminal amide. It is not a recognised pharmaceutical, and it is a recent research-market compound. Its parent, Semax, is covered in What is Semax.
Research use only. This overview summarises published laboratory and animal research. Baltic Peptides supplies this compound for in-vitro and preclinical research by qualified researchers; it is not a medicine and is not for human or veterinary use.
Chemical structure and specifications
| Property | Adamax 1032 Da | “Adamax” 984 Da |
|---|---|---|
| Formula | C50H69N11O11S | C44H61N11O13S |
| Average mass | 1032.23 g/mol | 984.1 g/mol |
| Structure | Ac-MEHFPGP + adamantane unit, C-terminal amide | Ac-MEHFPGPAG-OH, no adamantane |
| CAS number | None assigned | None assigned |
I confirmed that the formula for the 1032 Da form equals acetylated MEHFPGP joined to 3-aminoadamantane-1-carboxamide, which is the connectivity shown in the Wikipedia entry’s SMILES; the supplier states that the exact connectivity has not been published, so treat the depiction as unconfirmed. The 984 Da formula equals Ac-MEHFPGPAG-OH. The two share a Semax core and N-acetyl cap and differ in the C-terminus, so they are not interchangeable.
Discovery and research history
Adamax appeared in the research-peptide market in the mid-2020s. The Wikipedia entry for Adamax states that it has been identified as a designer drug in border seizures and that its classification as a prescription medicine in New Zealand has been suggested, citing a June 2025 submission to Medsafe’s Medicines Classification Committee. I did not open that submission.
Its lineage has two sources: Semax from Russian neuropeptide research, and P021, an adamantylglycine-modified research peptide derived from ciliary neurotrophic factor, according to the supplier. No discovery paper for Adamax was found.
Design rationale and what is unknown
Design hypotheses
The N-acetyl cap is expected to slow aminopeptidase cleavage, and the bulky lipophilic adamantane cage is expected to raise lipophilicity and resist enzymatic breakdown. N-terminal acetylation is known to protect some peptides from DPP-IV (N-terminal acetylation protects GLP-1-(7-34)-amide from DPP-IV degradation), but protection is peptide-specific.
What is not established
No receptor, pathway or pharmacokinetic study of Adamax was found. The BDNF/TrkB framing in supplier materials is extrapolated from Semax and should be treated as a hypothesis. For that reason, this article draws the diagram as composition and status, not as a signalling mechanism.
Main research areas
- Analytical chemistry: confirming mass and separating the 1032 Da and 984 Da materials.
- Stability and lipophilicity assays: comparison with Semax and N-Acetyl Semax Amidate in vitro.
- Structure-activity design: use of adamantane cages in peptide modification.
- Parent-compound research: Semax studies, in the Semax article.
What published studies actually show
| Evidence type | What is reported |
|---|---|
| Chemical facts | Formula and mass are defined; connectivity is shown in one encyclopaedic source and not independently published. |
| Peer-reviewed studies | None found for Adamax itself. |
| Parent compound | Semax literature exists but is not transferable. |
| Regulatory | No approval anywhere according to the supplier; reported as a designer drug in border seizures. |
Claims of large potency gains over Semax circulate in vendor material. None was found in the peer-reviewed literature.
Scientific limitations and open questions
- No peer-reviewed study of Adamax itself was found.
- Two different molecules are sold under the same name, and the supplier states that the exact connectivity of the 1032 Da form has not been published.
- The adamantane benefits are design hypotheses.
- It has no CAS number, no approval, and has been reported in border seizures as a designer drug.
Analytical and laboratory considerations
Because two molecules share the name, mass confirmation is the key identity test: the 1032 Da form should show about 1032.2 Da, and the 984 Da material about 984.1 Da. HPLC should resolve Met-sulfoxide (+16 Da) because methionine remains exposed. The adamantane cage makes the molecule markedly more hydrophobic, so it retains longer on reverse-phase HPLC than Semax.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the Adamax product page.
Sources and further reading
- Adamax, Wikipedia (citing the June 2025 Medsafe submission “Classification of Unscheduled Peptides”). Wikipedia
- N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity (2008). PubMed
- Rational design and delivery of engineered peptides (2026 review), on terminal capping. PMC
All Baltic Peptides products are supplied strictly for laboratory research use. They are not medicines, supplements or food and are not for human or animal use. This article summarises published research for educational purposes only and does not describe any use in people.
FAQ
Common questions
What is Adamax?
What is the difference between Adamax 1032 Da and 984 Da?
What is the molecular weight of Adamax?
Is there published research on Adamax?
What does the adamantane group do?
How is Adamax different from N-Acetyl Semax Amidate?
Is Adamax an approved medicine?
Keep reading
Related reading
Adamax (1032 Da)
Current batches, formats and the COA for Adamax.
What is Semax?
The ACTH(4-7)-derived parent peptide.
What is N-Acetyl Semax Amidate?
The simple double-capped Semax form, for comparison.
Research-grade Adamax, tested before it ships
Independent HPLC and mass spec results for every batch, dispatched from the EU.
